From streamlining clinical trials to evaluating drug repurposing possibilities for new patient populations and addressing critical supply chain challenges, 2024 will be the year artificial
We find ourselves at the cutting edge of oncology innovation, with the ADC field booming with excitement due to the constant eflux of clinical progress and a plethora of high-value collabor